Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$11.75 USD
-0.79 (-6.30%)
Updated May 13, 2024 04:00 PM ET
After-Market: $11.78 +0.03 (0.26%) 4:22 PM ET
3-Hold of 5 3
F Value B Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Zentalis Pharmaceuticals, Inc. [ZNTL]
Reports for Purchase
Showing records 41 - 60 ( 69 total )
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Zentalis Highlights ZN-c3s Progress Across Multiple Indications; Reit Buy and Raising Our PT to $120 From $80
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; WEE1 Clinical Development Expansion Continues; R&D Day Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; WEE1i ZN-c3 Dataset Improves as Program Broadens
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Trial Starts Across Pipeline Define 2H21; Reit Buy and $80 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Expecting Interim Results for ZN-c5 Program in 2Q21; Reit Buy and Raising PT to $80
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
WEE1 Inhibition Exhibited Partial Responses in Advanced Solid Tumors at Late-Breaker AACR 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Ph 1 WEE1 Inhibitor ZN-c3 Data: Exceptional Responses; Favorable Safety Profile
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R